11 results match your criteria: "Epicentre Paris[Affiliation]"
Vaccine
April 2024
MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda; London School of Hygiene and Tropical Medicine, London, United Kingdom.
Background: Understanding the knowledge, perception and attitudes towards Ebola vaccines is an important factor in ensuring future use of these vaccines. A qualitative methods study embedded in an Ebola vaccine immunogenicity and safety trial (NCT04028349) was conducted to explore the knowledge and perceptions of healthcare (HCWs) and frontline workers (FLWs), about Ebola vaccines and their willingness to participate or recommend participation in Uganda.
Method: We carried out focus group discussions and semi-structured interviews before and after vaccination, with 70 HCWs and FLWs who consented to participate in the trial, and in the qualitative component, from August to September 2019.
Am J Trop Med Hyg
September 2023
Research Department, Epicentre Paris, Paris, France.
In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a rapidly emerging virus causing the coronavirus disease 2019 (COVID-19) pandemic, had no known effective prophylaxis and no widely available proven effective antiviral treatment. Hydroxychloroquine/Chloroquine was identified as an early potential therapeutic candidate drawing on evidence from reports of both in vitro and in vivo testing. A multicountry placebo-controlled randomized trial was set to evaluate the use of hydroxychloroquine/chloroquine to prevent infection in healthcare workers and staff working in a health facility involved in COVID-19 management.
View Article and Find Full Text PDFBackground: The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
Objectives: We assessed the feasibility and acceptability of using the FujiLAM test at point of care in outpatient settings.
Methods: We conducted a mixed methods study in four outpatient settings in Kenya, Mozambique, South Africa, and Uganda between November 2020 and September 2021.
Xpert MTB/RIF (Xpert) and culture are the most reliable methods for tuberculosis diagnosis but are still poorly accessible in many low-resource countries. We aimed to assess the effects of OMNIgene Sputum (OM-S) and ethanol in preserving sputum for Xpert and OM-S for mycobacterial growth indicator tube (MGIT) testing over periods of 15 and 8 days, respectively. Sputum samples were collected from newly diagnosed smear-positive patients.
View Article and Find Full Text PDFAm J Respir Crit Care Med
November 2018
2 Médecins Sans Frontières Paris, France.
Am J Respir Crit Care Med
October 2016
8 Harvard Medical School Boston, Massachusetts.
Pediatr Infect Dis J
February 2016
From the *Epicentre Mbarara Research Centre, Uganda; †Mbarara University of Science and Technology, Uganda; ‡Epicentre Paris, France; and §IRD UMI233/INSERM U1175/Université de Montpellier, France.
Background: Difficulty to obtain sputum in children complicates diagnosis of intrathoracic tuberculosis (TB). The intragastric string test (ST) used for retrieval of enteric pathogens might be an alternative specimen collection method but requires further evaluation of its utility in TB diagnosis. We conducted a cross-sectional study comparing the TB detection yield and the tolerability of ST and sputum induction (SI) in children.
View Article and Find Full Text PDFBull World Health Organ
September 2015
MSF, Access Campaign, Geneva, Switzerland .
Objective: To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associated with invalid results.
Methods: We collated 25,616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire.
Am J Respir Crit Care Med
July 2015
9 Médecins Sans Frontières Paris, France.
PLoS One
October 2015
Epicentre Mbarara Research Centre, Mbarara, Uganda; Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.
Background: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy.
View Article and Find Full Text PDFAm J Respir Crit Care Med
February 2015
1 Epicentre Paris, France.